<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971408</url>
  </required_header>
  <id_info>
    <org_study_id>B3724-P</org_study_id>
    <nct_id>NCT04971408</nct_id>
  </id_info>
  <brief_title>Impact of Passive Heat on Metabolic, Inflammatory and Vascular Health in Persons With Spinal Cord Injury</brief_title>
  <acronym>SCIPHS</acronym>
  <official_title>Passive Heating as an Accessible and Tolerable Strategy to Improve the Inflammatory Profile and Cardiometabolic Health in People With Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      SCI results in higher incidence of heart disease and diabetes and heart disease is the most&#xD;
      common cause of death. Chronic inflammation, deleterious changes in vascular structure and&#xD;
      impaired glucose metabolism are risk factors that contribute to both heart disease and&#xD;
      diabetes. While exercise can help reduce these risk factors, paralysis and impaired&#xD;
      accessibility often precludes exercise in persons with SCI. New research in able-bodied&#xD;
      persons demonstrates passive heating decreases inflammation and improves vascular function.&#xD;
      Similar studies in persons with SCI suggest they may also have the same health benefits&#xD;
      however these studies only investigated the impact of short term (one episode) passive&#xD;
      heating (as opposed to repeated bouts). Repeated bouts of heat exposure will likely be&#xD;
      required to impact chronic inflammation, but this has never been tested in persons with SCI.&#xD;
      This study will test the impact of repeated bouts (3x/week) of passive heat stress over a&#xD;
      longer term (8 weeks) on inflammation, metabolism and vascular function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2022</start_date>
  <completion_date type="Anticipated">December 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>passive heat stress with water perfused heat suits and electrical heating blankets</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>inflammatory markers</measure>
    <time_frame>change from 0 to 8 to 16 weeks</time_frame>
    <description>IL-1 beta</description>
  </primary_outcome>
  <primary_outcome>
    <measure>glucose metabolism via oral glucose tolerance test</measure>
    <time_frame>change from 0 to 8 to 16 weeks</time_frame>
    <description>oral glucose tolerance test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammatory marker</measure>
    <time_frame>change from 0 to 8 to 16 weeks</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammation</measure>
    <time_frame>change from 0 to 8 to 16 weeks</time_frame>
    <description>TNF-alpha</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammation</measure>
    <time_frame>change from 0 to 8 to 16 weeks</time_frame>
    <description>IL-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammation</measure>
    <time_frame>change from 0 to 8 to 16 weeks</time_frame>
    <description>Heat shock protein 72</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endothelial function</measure>
    <time_frame>change from 0 to 8 to 16 weeks</time_frame>
    <description>cutaneous vascular conductance measured via laser doppler flowmetry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Spinal Cord Injury</condition>
  <condition>Chronic Inflammation</condition>
  <condition>Glucose Metabolism</condition>
  <condition>Endothelial Function</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>passive heat stress x1 visit then no intervention for 8 weeks. participants continue regular exercise habits as usual.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Passive heat stress</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After arm 1, passive heat stress 3x/week x8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>passive heat stress</intervention_name>
    <description>as above</description>
    <arm_group_label>Passive heat stress</arm_group_label>
    <other_name>water perfused suit and electrical heating blanket</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>participant engage in activity as usual</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable SCI over 1 year of duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons who smoke cigarettes&#xD;
&#xD;
          -  Daily administration of anti-inflammatory medications&#xD;
&#xD;
          -  Daily administration of vasoactive medications&#xD;
&#xD;
          -  Pressure ulcer stage 3 or 4&#xD;
&#xD;
          -  History of heat related illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle B Trbovich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Texas Health Care System, San Antonio, TX</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle B Trbovich, MD</last_name>
    <phone>(210) 617-5300</phone>
    <phone_ext>16986</phone_ext>
    <email>michelle.trbovich@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Stowe</last_name>
    <phone>(210) 617-5300</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>South Texas Health Care System, San Antonio, TX</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michelle B Trbovich, MD</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>16986</phone_ext>
      <email>michelle.trbovich@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Stowe</last_name>
      <phone>(210) 617-5300</phone>
    </contact_backup>
    <investigator>
      <last_name>Michelle B Trbovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

